Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Daratumumab + Lenalidomide + Dexamethasone for Multiple Myeloma
Recruiting2 awardsPhase 3
Halifax, Nova Scotia
This trial looks at whether adding daratumumab to lenalidomide and dexamethasone improves progression-free survival in people with relapsed or refractory multiple myeloma.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.